Member Info for lostinspace69

very interesting and useful to further understand the mechanism behind Affinmer/PreCision platform. Something tells me that AS won't be needing to take on low rent gigs like that in future though. This company is going places.

jfellow, you are correct. ODX announced their plans to produce a range of tests with Mologic and one of those is a LFT antigen test. I can't see any further details regarding how the test will work or timescales. I think Avacta is a long way ahead, and has the right partner with Cytiva and others to be announced soon.

bought ODX for the first time today. For me, it's more investible as a result of the placing.

I think there was a realisation yesterday that when positive results from trials are released, it will be global news, similar to what we saw with dexamethasone. Also, a greater realisation that early stage treatments are the answer and covid isn't going away anytime soon

50p + would be nice. With strong near term news flow expected, I wouldn't want to be out of this stock right now.

If they were struggling to get the numbers, which is entirely feasible, then they surely won't have a problem getting candidates now. I can't see that this would have been extended nationwide, unless there was some clear evidence it is beneficial.

alwayswhining - read it again; Affimer reagents prevent infection of human cells by a SARS-COV-2 model virus. This is huge news and could change the direction of not only SARS-COV-2, but also other future virus pandemics.

Incredible news and groundbreaking progress from the teams at Avacta and Glasgow University. This clearly showcases just one of the many potential uses for affimers.

Not the best presentation, but it was never meant to be for the benefit of investors, so you have to look at it in that context. The purpose was to discuss the challenges amongst peers, and that's what they did, perhaps a little too much lol. I am holding and confident we will see a VERY positive update before month end.

I think David just had his knuckles wrapped

sona branding very 1990's. I hate those roll up marketing boards. looks so cheap.

GabrielOak - for me it was a bit of a car crash, but it's more about the individuals and the way they presented themselves. I am. not concerned about my investment. I am still expecting a VERY positive RNS before the month end.

I actually don't think this webinar was really very relevant, as all it focused on was the challenges and issues, which I am 100% confident can ALL be overcome. So, not really sure what the purpose was, other than to debate those challenges. This makes zero difference to the outcome. if anything, I am more confident now, having seen SONA CEO speak.

I am up to my neck in AVACTA, but I have to say.... that was a car crash!

Myles recently commented; It's improbable that Cytiva would host a public panel discussion on its work in developing #COVID19 POC tests., UNLESS of course it has ALREADY implemented "the solutions that exist to overcome... design challenges encountered during development".

I have to say that I definitely didn’t get that feeling. Anyone else care to comment ?

These speakers definitely haven’t been briefed by the PR teams

Lots of talk about scaling issues. Issues with getting reagents, issues with getting materials, issues with scaling manufacturing. Gives a sense of the challenge and one perhaps also highlights the advantage and benefits of Affimer platform ?!

The guy from Sona looks a bit wet behind the ears

David from Avacta points out that getting access to the materials is a problem that needs to be overcome

I think AVACTA stands out from the AIM crowd. Innovative and disruptive with the potential to enter both new and existing markets with world beating products. I am as long as long can be and never felt more confident. It's only a matter of "when" not "if"